Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck nasonex (mometasone, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%)
Form 8-K Table 3a / 3b Product Sales
Latest, Q1 2021
-65.0%
Period ended Mar 31, 2021
Change on a year earlier
–
History
7 quarters
Since Q4 2017
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nasonex (mometasone, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q1 2021 | Mar 31, 2021 | -65.0% | – | Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗ |
| Q4 2019 | Dec 31, 2019 | -53.0% | +7.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| Q3 2019 | Sep 30, 2019 | -40.0% | -169.0 pts | Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗ |
| Q1 2019 | Mar 31, 2019 | -152.0% | – | Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗ |
| Q4 2018 | Dec 31, 2018 | -60.0% | -120.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| Q3 2018 | Sep 30, 2018 | 129.0% | – | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 60.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Nasonex (mometasone, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%), quarterly Q4 2017–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_nasonex_us_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.